Deka Bank Deutsche Girozentrale Novavax Inc Transaction History

Deka Bank Deutsche Girozentrale

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$6.81 - $9.74 $306,450 - $438,300	45,000 New	45,000 $322,000
Q4 2022 Feb 01, 2023	SELL	$8.86 - $25.04 $17,277 - $48,828	-1,950 Reduced 7.54%	23,900 $230,000
Q2 2022 Aug 03, 2022	SELL	$36.28 - $75.29 $498,668 - $1.03 Million	-13,745 Reduced 34.71%	25,850 $1.3 Million
Q1 2022 Apr 28, 2022	BUY	$69.73 - $142.9 $252,910 - $518,298	3,627 Added 10.08%	39,595 $3 Million
Q4 2021 Feb 02, 2022	SELL	$134.56 - $217.97 $14,128 - $22,886	-105 Reduced 0.29%	35,968 $5.46 Million
Q3 2021 Oct 22, 2021	BUY	$177.8 - $270.58 $1.14 Million - $1.74 Million	6,432 Added 21.7%	36,073 $7.42 Million
Q2 2021 Aug 05, 2021	BUY	$121.0 - $257.67 $1.17 Million - $2.48 Million	9,641 Added 48.21%	29,641 $6.2 Million
Q4 2020 Mar 12, 2021	BUY	$78.74 - $139.5 $1.57 Million - $2.79 Million	20,000 New	20,000 $2.39 Million
Q3 2019 Nov 14, 2019	SELL	$4.02 - $7.84 $40,642 - $79,262	-10,110 Closed	0 $0
Q2 2019 Aug 01, 2019	BUY	$4.93 - $12.2 $49,842 - $123,342	10,110 New	10,110 $62,000

290

93.4M

6.95M

9.4M

Ticker NVAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,215,104
Market Cap $666M
Description
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...

Get notified when there are updates to the investment portfolio of Deka Bank Deutsche Girozentrale, based on Form 13F filings with the SEC.

Stay updated on Deka Bank Deutsche Girozentrale with notifications on news.